Omega-3 and Heart Health: The Definitive Meta-Analysis

Omega-3 and the Heart: What Does the Strongest Evidence Say?

Omega-3 fatty acids and heart health is one of the most researched topics in nutritional science. Studies involving tens of thousands of participants have provided an increasingly clear picture. A 2019 meta-analysis brought this evidence together.

Hu et al. (2019): The Definitive Meta-Analysis

This Journal of the American Heart Association (JAHA) article analysed 13 randomised controlled trials totalling 127,477 participants.

Key Meta-Analysis Results

Dose-Response Relationship

An important finding: the effect was dose-dependent. This means higher EPA+DHA doses were associated with greater risk reduction. Each additional 1 g/day increase in EPA+DHA intake was associated with further risk reduction.

The VITAL Study (Manson et al. 2019)

VITAL (VITamin D and OmegA-3 TriaL) is one of the largest omega-3 randomised controlled trials, involving over 25,000 participants.

Study design:

• 25,871 participants (men >=50 years, women >=55 years)
• 840 mg EPA+DHA per day (Omacor/Lovaza)
• Mean follow-up: 5.3 years
• Double-blind, placebo-controlled

Key results:

• Major cardiovascular events: 8% risk reduction (entire cohort)
• Myocardial infarction: 28% risk reduction
• Notable: the greatest benefit appeared in people who ate less fish in their usual diet
• In the low fish consumption group (fewer than 1.5 servings/week): 19% lower risk of major cardiovascular events

EFSA-Approved Claims

The European Food Safety Authority (EFSA) has approved the following health claims for omega-3 fatty acids:

Heart health claim:

• "EPA and DHA contribute to the normal function of the heart" — on condition that at least 250 mg EPA and DHA per day are consumed

Triglycerides claim:

• "EPA and DHA contribute to the maintenance of normal blood triglyceride levels" — on condition that 2 g EPA and DHA per day are consumed

Blood pressure claim:

• "EPA and DHA contribute to the maintenance of normal blood pressure" — on condition that 3 g EPA and DHA per day are consumed

These are the only EFSA-approved omega-3 claims related to heart health.

What Does This Mean in Practice?

Minimum Recommended Intake

Different organisations recommend:

• EFSA: 250 mg EPA+DHA per day (normal heart function)
• American Heart Association (AHA): 2 servings of oily fish per week (~500 mg EPA+DHA per day)
• ISSFAL (International Society for the Study of Fatty Acids and Lipids): 500 mg EPA+DHA per day

Sources

Food sources:

• Salmon: ~1,800 mg EPA+DHA / 100 g
• Mackerel: ~1,500 mg EPA+DHA / 100 g
• Sardines: ~1,400 mg EPA+DHA / 100 g
• Herring: ~1,200 mg EPA+DHA / 100 g
• Tuna: ~300 mg EPA+DHA / 100 g

Supplements:

• Fish oil: typically 300–500 mg EPA+DHA per capsule
• Concentrated fish oil: up to 900+ mg EPA+DHA per capsule
• Algae oil: typically DHA-rich, some also contain EPA

Limitations and Context

While the evidence base is strong, several nuances should be noted:

1. Individual study results vary — not all studies showed benefit (e.g. the ASCEND trial in diabetics)
2. Dose matters — low doses (<1 g/day) show more modest effects than high doses
3. Baseline matters — people already eating plenty of fish derive less additional benefit from supplements
4. EPA vs DHA — some studies suggest EPA may be more important for heart health
5. Supplement =/= healthy diet — omega-3 is one part of a comprehensive heart-healthy lifestyle

Summary

A meta-analysis of 127,477 participants and large studies like VITAL confirm that marine omega-3 fatty acids (EPA and DHA) are associated with reduced cardiovascular disease risk. EFSA has approved the claim that EPA and DHA contribute to the normal function of the heart at an intake of at least 250 mg per day.

References

1. Hu, Y., Hu, F. B., & Manson, J. E. (2019). Marine omega-3 supplementation and cardiovascular disease: An updated meta-analysis of 13 randomized controlled trials involving 127,477 participants. Journal of the American Heart Association, 8(19), e013543. https://doi.org/10.1161/JAHA.119.013543
2. Manson, J. E., Cook, N. R., Lee, I.-M., et al. (2019). Marine n-3 fatty acids and prevention of cardiovascular disease and cancer. New England Journal of Medicine, 380(1), 23–32. https://doi.org/10.1056/NEJMoa1811403
3. EFSA Panel on Dietetic Products, Nutrition and Allergies (2010). Scientific Opinion on the substantiation of health claims related to eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA). EFSA Journal, 8(10), 1796.
4. EFSA Panel on Dietetic Products, Nutrition and Allergies (2009). Scientific Opinion on the substantiation of a health claim related to EPA and DHA and maintenance of normal blood pressure. EFSA Journal, 7(9), 1263.
5. Bowman, L., Mafham, M., Wallendszus, K., et al. (ASCEND Study Collaborative Group) (2018). Effects of n-3 fatty acid supplements in diabetes mellitus. New England Journal of Medicine, 379(16), 1540–1550. https://doi.org/10.1056/NEJMoa1804989

Read more:

• Omega-3 products at MaxFit

Disclaimer

Dietary supplements are not a substitute for a varied, balanced diet and healthy lifestyle.